Veracyte Inc. (VCYT)

30.93
NASDAQ : Health Technology
Prev Close 29.85
Day Low/High 29.85 / 31.18
52 Wk Low/High 8.77 / 30.25
Avg Volume 711.70K
Exchange NASDAQ
Shares Outstanding 47.97M
Market Cap 1.43B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Veracyte To Release Second Quarter 2019 Financial Results On July 30, 2019

Veracyte To Release Second Quarter 2019 Financial Results On July 30, 2019

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the second quarter 2019 after the close of market on Tuesday, July 30, 2019.

Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available To Physicians For Improved Lung Cancer Diagnosis

Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available To Physicians For Improved Lung Cancer Diagnosis

Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has begun making its next-generation Percepta ® Genomic Sequencing Classifier (GSC) available to physicians, providing them with expanded lung cancer risk...

Veracyte Named A San Francisco Bay Area "Top Workplace" For Sixth Consecutive Year

Veracyte Named A San Francisco Bay Area "Top Workplace" For Sixth Consecutive Year

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that the company has been awarded a Top Workplaces 2019 honor by the Bay Area News Group for the sixth consecutive year.

Veracyte Announces New Article Published In Cancer Cytopathology Detailing Clinical Utility Of Its RNA Sequencing-Based Testing For Thyroid Cancer Diagnosis And Treatment

Veracyte Announces New Article Published In Cancer Cytopathology Detailing Clinical Utility Of Its RNA Sequencing-Based Testing For Thyroid Cancer Diagnosis And Treatment

Veracyte, Inc. (Nasdaq: VCYT) announced today that a review article in Cancer Cytopathology , a journal of the American Cancer Society, details how new RNA whole-transcriptome sequencing-based genomic testing is helping physicians overcome a range of...

Veracyte Announces New Publication Of Data Demonstrating Real-World Performance Of The Afirma GSC In Thyroid Cancer Diagnosis

Veracyte Announces New Publication Of Data Demonstrating Real-World Performance Of The Afirma GSC In Thyroid Cancer Diagnosis

Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company's Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary...

Veracyte Announces New Data Showing Potential Of Afirma Genomic Test To Guide Targeted Treatment For Medullary Thyroid Cancer Concurrent With Diagnosis

Veracyte Announces New Data Showing Potential Of Afirma Genomic Test To Guide Targeted Treatment For Medullary Thyroid Cancer Concurrent With Diagnosis

Veracyte, Inc. (Nasdaq: VCYT) today announced new data demonstrating the potential for its Afirma ® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients with a rare but aggressive form of thyroid cancer concurrent with...

February 2020 Options Now Available For Veracyte (VCYT)

February 2020 Options Now Available For Veracyte (VCYT)

Investors in Veracyte Inc saw new options begin trading today, for the February 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 266 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Veracyte Announces Participation In Two Upcoming Investor Conferences

Veracyte Announces Participation In Two Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H.

Veracyte Announces New Data Demonstrating Afirma Xpression Atlas's Potential To Inform Treatment Selection For Patients With Medullary Thyroid Cancer To Be Presented At 2019 ASCO Annual Meeting

Veracyte Announces New Data Demonstrating Afirma Xpression Atlas's Potential To Inform Treatment Selection For Patients With Medullary Thyroid Cancer To Be Presented At 2019 ASCO Annual Meeting

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data demonstrating the Afirma® Xpression Atlas test's ability to detect gene alterations that may be targeted by new treatments for medullary thyroid cancer - a rare, but aggressive form of thyroid...

Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier For Improved Lung Cancer Diagnosis

Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier For Improved Lung Cancer Diagnosis

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta ® Genomic Sequencing Classifier (GSC) provides expanded lung cancer risk information that can further guide next...

Veracyte Names Sangeeta Bhorade, M.D., Medical Director Of Pulmonology

Veracyte Names Sangeeta Bhorade, M.D., Medical Director Of Pulmonology

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade, M.

Veracyte To Present At The UBS Global Healthcare Conference

Veracyte To Present At The UBS Global Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H.

Veracyte Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Veracyte Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters' option to purchase additional shares, at a price to the public of...

Veracyte Announces Pricing Of Public Offering Of 5,500,000 Shares Of Common Stock

Veracyte Announces Pricing Of Public Offering Of 5,500,000 Shares Of Common Stock

Veracyte, Inc. (Nasdaq: VCYT) (the "Company") today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.

Veracyte Announces Proposed Public Offering Of Common Stock

Veracyte Announces Proposed Public Offering Of Common Stock

Veracyte, Inc. (Nasdaq: VCYT) ("the Company") today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

Veracyte Announces First Quarter 2019 Financial Results

Veracyte Announces First Quarter 2019 Financial Results

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.

Veracyte Receives Regulatory Authorization To Offer Envisia Genomic Classifier For Patients In New York State

Veracyte Receives Regulatory Authorization To Offer Envisia Genomic Classifier For Patients In New York State

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State Department of Health to offer the Envisia™ Genomic Classifier for patients in the state effective...

Veracyte Names Alfred Bowie, Jr., Ph.D., As Vice President, Corporate And Business Development (Photo: Business Wire)

Veracyte Names Alfred Bowie, Jr., Ph.D., As Vice President, Corporate And Business Development (Photo: Business Wire)

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred "Freddie" Bowie, Jr.

Veracyte Announces Publication Highlighting Afirma GSC's Ability To Rule Out Cancer In Challenging Thyroid Nodule Subtype

Veracyte Announces Publication Highlighting Afirma GSC's Ability To Rule Out Cancer In Challenging Thyroid Nodule Subtype

Veracyte, Inc. announced today that a new study published online in BMC Systems Biology showcases the development of the Afirma ® Genomic Sequencing Classifier (GSC) and its ability to distinguish benign from likely-cancerous Hürthle cells, a common, but...

Veracyte To Release First Quarter 2019 Financial Results On April 30, 2019

Veracyte To Release First Quarter 2019 Financial Results On April 30, 2019

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019.

Veracyte Announces Data Published In The Lancet Respiratory Medicine Demonstrate That The Envisia Genomic Classifier Improves Diagnosis Of IPF

Veracyte Announces Data Published In The Lancet Respiratory Medicine Demonstrate That The Envisia Genomic Classifier Improves Diagnosis Of IPF

Veracyte, Inc. announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company's Envisia Genomic Classifier improves diagnosis for patients undergoing evaluation for interstitial lung diseases (ILDs),...

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

Veracyte Announces Participation In The 18th Annual Needham Healthcare Conference

Veracyte Announces Participation In The 18th Annual Needham Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H.

Veracyte Announces New Afirma Xpression Atlas Data That Advance Genomic Understanding Of Medullary Thyroid Cancer

Veracyte Announces New Afirma Xpression Atlas Data That Advance Genomic Understanding Of Medullary Thyroid Cancer

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.

Interesting VCYT Put And Call Options For May 17th

Interesting VCYT Put And Call Options For May 17th

Investors in Veracyte Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCYT options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Veracyte Announces Sponsorship Of The Climb To Fight Cancer's Team Kilimanjaro Expedition

Veracyte Announces Sponsorship Of The Climb To Fight Cancer's Team Kilimanjaro Expedition

Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its "Summit" level sponsorship of the Climb to Fight Cancer's Team Kilimanjaro expedition as part of the company's expanded efforts to combat this disease.

Veracyte Announces New Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019

Veracyte Announces New Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine Society's annual...

Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier

Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier

Veracyte, Inc. (Nasdaq: VCYT) announced today that it has received a final Medicare local coverage determination (LCD) for the Envisia™ Genomic Classifier.

TheStreet Quant Rating: D (Sell)